Boston Scientific/Corautus Genetics
This article was originally published in The Gray Sheet
Executive Summary
Phase IIb pivotal trial receives FDA go-ahead to evaluate Vascular Endothelial Growth Factor-2 for treating severe coronary artery disease. Corautus' factor will be delivered through Boston Scientific's Stiletto endocardial direct-injection catheter under a strategic alliance begun in July 2003. The randomized, double-blinded trial, set to commence in Q3, will enroll up to 404 patients in as many as 20 U.S. centers. The study likely will finish by July 2005...